UBS Group
SMMT icon

UBS Group’s Summit Therapeutics SMMT Stock Holding History

UBS Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$379K Buy
+20,000
New +$323K ﹤0.01% 6266
2025
Q4 		– Sell
-85,000
Closed -$1.76M – 11102
2025
Q3 		$1.76M Buy
+85,000
New +$2.06M ﹤0.01% 5080

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's SMMT Position: Q1 2026 in Review

UBS Group increased its Summit Therapeutics (SMMT) stake by 323% in Q1 2026, buying an estimated $45.4M and bringing the position to 3,680,315 shares worth $69.8M. The position accounts for 0.01% of the portfolio, ranked #1318.

UBS Group first reported a position in SMMT in Q2 2015 and has held it in 36 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • UBS Group held 3,680,315 shares of Summit Therapeutics worth $69.8M as of Q1 2026.
  • UBS Group bought 2,809,596 Summit Therapeutics shares in Q1 2026, an estimated $45.4M.
  • Summit Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1318 holding.
  • UBS Group first reported a position in Summit Therapeutics in Q2 2015 and has held it in 36 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.